首页 › 弥漫性大B细胞淋巴瘤 › 伊利诺伊州 › Chicago
Chicago IL 弥漫性大B细胞淋巴瘤临床试验
18项针对 弥漫性大B细胞淋巴瘤的研究正在 Chicago及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
招募中2 期
- Northwestern University, Chicago
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
招募中2 期
- University of Chicago Medical Center ( Site 0126), Chicago
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- The University of Chicago Medical Center (UCMC), Chicago
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
招募中1 期
- University of Chicago Comprehensive Cancer Center, Chicago
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- Northwestern University - Feinberg School of Medicine, Chicago
- Rush University Medical Center, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- University of Chicago, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- University of Chicago Medical Center, Chicago
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
招募中观察性研究
- Robert H Lurie Cancer Center, Chicago
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- Northwestern, Chicago
- University of Chicago, Chicago
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- Robert H Lurie Cancer Center, Chicago
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
招募中1 期
- University of Illinois at Chicago, Chicago
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
招募中1 期
- Northwestern University, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Northwestern University, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
招募中1/2 期
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- The University of Chicago Medical Center, Chicago
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
招募中2 期
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
招募中2 期
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- University of Chicago, Chicago
其他城市的 弥漫性大B细胞淋巴瘤试验
- New York City, NY21 项研究
- Baldwin Park, CA19 项研究
- Houston, TX17 项研究
- Los Angeles, CA17 项研究
- Milwaukee, WI16 项研究
- Boston, MA16 项研究
- Philadelphia, PA15 项研究
- Portland, OR15 项研究
- Durham, NC14 项研究
- Nashville, TN14 项研究
- Dallas, TX13 项研究
- Seattle, WA12 项研究
Chicago的其他研究
- 非小细胞肺癌62 项研究
- 乳腺癌58 项研究
- 癌症（所有类型）53 项研究
- 转移性癌症45 项研究
- 前列腺癌45 项研究
- 肥胖症42 项研究
- 肺癌41 项研究
- 卵巢癌36 项研究
- 卒中35 项研究
- 心力衰竭32 项研究
- 结直肠癌32 项研究
- 超重28 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年9月30日。每项研究自行设定入选标准，由研究团队决定谁能参与。